Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Lincoln Pharmaceuticals Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
The presentation does not provide any specific revenue, sales, or volume figures for the quarter. The presentation reports the following for the quarter: - EBITDA: ₹26 crore, a 3% year-on-year increase - Operating Margin: 17.3%, a 150 basis points improvement year-on-year - Profit After Tax (PAT): ₹18 crore, an 8% year-on-year increase Regarding margin outlook: - The presentation does not explicitly state any future margin outlook for EBITDA or operating margin.
From Lincoln Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹187 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q4 FY26 results?
The presentation does not provide any specific revenue, sales, or volume figures for the quarter. The presentation reports the following for the quarter: - EBITDA: ₹26 crore, a 3% year-on-year increase - Operating Margin: 17.3%, a 150 basis points improvement year-on-year - Profit After Tax (PAT): ₹18 crore, an 8% year-on-year increase Regarding margin outlook: - The presentation does not explicitly state any future margin outlook for EBITDA or operating margin.
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.
Is Lincoln Pharmaceuticals Ltd planning capital expenditure?
The investor presentation does not provide any information on capex, capacity expansion, new plant, or projects, including amounts, status, or timelines.
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.